These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16932991)

  • 1. Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.
    Müller T; Welnic J; Muhlack S
    J Neural Transm (Vienna); 2007 Mar; 114(3):347-50. PubMed ID: 16932991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease.
    Müller T; Muhlack S
    Clin Neuropharmacol; 2007; 30(2):101-6. PubMed ID: 17414942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease.
    Müller T; Welnic J; Woitalla D; Muhlack S
    Neurosci Lett; 2007 Jul; 422(2):119-22. PubMed ID: 17590511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.
    Müller T; Muhlack S
    J Neural Transm (Vienna); 2008 Jun; 115(6):851-5. PubMed ID: 18335161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study.
    Kulisevsky J; Pascual-Sedano B; Barbanoj M; Gironell A; Pagonabarraga J; García-Sánchez C
    Mov Disord; 2007 Jan; 22(1):62-7. PubMed ID: 17115388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.
    Dingemanse J; Kleinbloesem CH; Zürcher G; Wood ND; Crevoisier C
    Br J Clin Pharmacol; 1997 Jul; 44(1):41-8. PubMed ID: 9241095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.
    Müller T; Woitalla D; Hauptmann B; Fowler B; Kuhn W
    Neurosci Lett; 2001 Jul; 308(1):54-6. PubMed ID: 11445284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection.
    Narożańska E; Białecka M; Adamiak-Giera U; Gawrońska-Szklarz B; Sołtan W; Schinwelski M; Robowski P; Madaliński MH; Sławek J
    Clin Neuropharmacol; 2014; 37(4):96-9. PubMed ID: 24992088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
    Kestenbaum M; Fahn S
    Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
    Müller T; Kuhn W
    Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
    Qu Y; Lai WL; Xin YR; Zhu FQ; Zhu Y; Wang L; Ding YP; Xu Y; Liu HF
    AAPS PharmSciTech; 2019 Sep; 20(8):312. PubMed ID: 31529266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
    Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
    Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
    Müller T; Kuhn W
    Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.